GLUE Monte Rosa Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: GLUE
Price (delayed)
$4.38
Market cap
$270.51M
P/E Ratio
12.17
Dividend/share
N/A
EPS
$0.36
Enterprise value
$237.26M
Highlights
The net income has soared by 119% YoY
Monte Rosa Therapeutics's EPS has soared by 116% YoY
The equity rose by 19% year-on-year but it has declined by 2.6% since the previous quarter
Key stats
What are the main financial stats of GLUE
Market
Valuations
Earnings
Shares outstanding
61.76M
Market cap
$270.51M
Enterprise value
$237.26M
Price to earnings (P/E)
12.17
Price to book (P/B)
1
Price to sales (P/S)
2.02
EV/EBIT
8.35
EV/EBITDA
6.45
EV/Sales
1.33
Revenue
$177.99M
Gross profit
$177.99M
Operating income
$14.96M
Net income
$24.17M
EBIT
$28.42M
EBITDA
$36.76M
Free cash flow
$23.85M
Per share
Balance sheet
Liquidity
EPS
$0.36
EPS diluted
$0.36
Free cash flow per share
$0.29
Book value per share
$4.36
Revenue per share
$2.17
TBVPS
$4.38
Total assets
$359.59M
Total liabilities
$91.51M
Debt
$41.13M
Equity
$268.08M
Working capital
$257.61M
Debt to equity
0.15
Current ratio
7.16
Quick ratio
7.12
Net debt/EBITDA
-0.9
Margins
Efficiency
Dividend
EBITDA margin
20.7%
Gross margin
100%
Net margin
13.6%
Operating margin
8.4%
Return on assets
6.4%
Return on equity
9.9%
Return on invested capital
13.2%
Return on capital employed
8.9%
Return on sales
16%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GLUE stock price
How has the Monte Rosa Therapeutics stock price performed over time
Intraday
3.55%
1 week
-8.56%
1 month
-13.44%
1 year
10.05%
YTD
-36.89%
QTD
-2.88%
Financial performance
How have Monte Rosa Therapeutics's revenue and profit performed over time
Revenue
$177.99M
Gross profit
$177.99M
Operating income
$14.96M
Net income
$24.17M
Gross margin
100%
Net margin
13.6%
The net income has soared by 119% YoY
The operating income has surged by 111% year-on-year
The net margin has surged by 101% year-on-year
The operating margin has surged by 100% year-on-year
Price vs fundamentals
How does GLUE's price correlate with its fundamentals
Growth
What is Monte Rosa Therapeutics's growth rate over time
Valuation
What is Monte Rosa Therapeutics stock price valuation
P/E
12.17
P/B
1
P/S
2.02
EV/EBIT
8.35
EV/EBITDA
6.45
EV/Sales
1.33
Monte Rosa Therapeutics's EPS has soared by 116% YoY
GLUE's P/B is 41% below its 5-year quarterly average of 1.7 and 29% below its last 4 quarters average of 1.4
The equity rose by 19% year-on-year but it has declined by 2.6% since the previous quarter
GLUE's price to sales (P/S) is 80% less than its last 4 quarters average of 10.1
Monte Rosa Therapeutics's revenue has increased by 12% QoQ
Efficiency
How efficient is Monte Rosa Therapeutics business performance
The ROIC has soared by 181% from the previous quarter and by 120% YoY
Monte Rosa Therapeutics's ROS has soared by 171% from the previous quarter and by 101% YoY
GLUE's ROE has soared by 114% year-on-year
Monte Rosa Therapeutics's ROA has soared by 114% YoY
Dividends
What is GLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GLUE.
Financial health
How did Monte Rosa Therapeutics financials performed over time
The company's current ratio rose by 28% QoQ and by 9% YoY
The quick ratio is up by 27% since the previous quarter and by 9% year-on-year
The debt is 85% smaller than the equity
The debt to equity has contracted by 25% YoY
The equity rose by 19% year-on-year but it has declined by 2.6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.